Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T17:31:40.828Z.
Calculation as of: 2026-10-06T17:31:40.828Z.
Quote observation: 2026-10-06T17:30:09.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5259cb07e2fbb96f0e8f0a81153900e7454c243d03e5865b91db876a0b9f3ffb
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$412.22M
EV/EBIT Ratio
N/A
TTM Avg
135.39x
3Y Avg
60.74x
5Y Avg
42.42x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | $424.32M | N/A | N/A | N/A | N/A |
| Tilray Brands, Inc. (TLRY)vs › | $424.40M | N/A | N/A | N/A | N/A |
| ARS Pharmaceuticals, Inc. (SPRY)vs › | $421.05M | N/A | N/A | N/A | N/A |
| Tectonic Therapeutic, Inc. (TECX)vs › | $429.12M | N/A | N/A | N/A | N/A |
| Senseonics Holdings, Inc. (SENS)vs › | $417.72M | N/A | N/A | N/A | N/A |
| NeoGenomics, Inc. (NEO)vs › | $432.32M | N/A | 64.08x | 60.43x | 132.37x |
| Assembly Biosciences, Inc. (ASMB)vs › | $434.58M | N/A | N/A | N/A | N/A |
| Myriad Genetics, Inc. (MYGN)vs › | $412.22M | N/A | 135.39x | 60.74x | 42.42x |
| Shoulder Innovations, Inc. (SI)vs › | $409.68M | N/A | N/A | N/A | N/A |
| Capricor Therapeutics, Inc. (CAPR)vs › | $438.52M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
